MonTa Biosciences

Spin-out from DTU focused on a novel cancer therapy that educates the immune system to fight cancer to cure patients with spreading of their disease.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Lyngby, Denmark
  • Currency USD
  • Founded March 2015
  • Employees 4
  • Incorporation Type Other
  • Website montabiosciences.com

Company Summary

Our vision is to develop a novel therapy to boost the immune system to cure cancer by combining immunotherapy with existing treatments.

We seek experienced investors to place 0.2-0.5 mUS$ together with a Danish Lead Investor with business, technical and scientific expertise.

ROI is expected between 25-50 fold in 6-8 years

Awarded with a 3 mUS$ grant to support future Development.

Business plan and slide deck upon request and signed NDA

Team

  • Simon Skjøde Jensen
    CEO

    PhD, Former Head of RnD, Group Leader, Experience in Business Development, Management, Entrepreneurship, Investor Relations, Drug Development, Drug Delivery, Cancer, Immunology

  • Thomas L. Andresen
    CSO

    Professor, group leader, entrepreneurship and start-up, drug delivery, chemistry, drug development, management, strong experience in attracting soft money

  • Jonas R. Henriksen
    COO

    Strong experience in GMP production, formulation technology, CMC and analytical methods

  • Ladan Parhamifar
    VP

    PhD, Pharmacology, Drug delivery and immunology

Advisors

Previous Investors

  • Copenhagen Spin Out
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free